| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
NMDA Receptor
|
|---|---|
| ln Vitro |
DL-AP5 (100 μM) partially prevents glutamate-induced increase in Arc/Arg3.1 protein levels[5]. DL-AP5 decreases the NMDA-induced Arc/Arg3.1 upregulation[5].
|
| ln Vivo |
DL-AP5 (0-10 μg/rat, Intra-CA1) significantly decreases the effect of NMDA[3]. DL-AP5 (0-10 nmol, Intracerebroventricular injection) causes a dose-dependent increase in food consumption[4]. DL-AP5 (5 nmol, Intracerebroventricular injection) attenuates the decreased food consumption induced by the intracerebroventricular injection of ghrelin[4].
|
| Animal Protocol |
Animal/Disease Models: Male Wistar rats (180-230 g)[3]
Doses: 1, 3.2 and 10 μg/rat Route of Administration: Injected into the intra-dorsal hippocampal (intra-CA1) immediately after shock administration, once Experimental Results: Significantly decreased the effect of NMDA (10-2 μg/rat, intra-CA1) with significant interaction. Animal/Disease Models: Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)[4] Doses: 0, 2.5, 5, and 10 nmol; in a volume of 10 μL Route of Administration: Intracerebroventricular injection Experimental Results: Caused a dose-dependent increase in food consumption which was significant for 5 and 10 nmol doses. Animal/Disease Models: Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)[4] Doses: 5 nmol Route of Administration: Intracerebroventricular injection, followed by ghrelin (0.6 nmol) Experimental Results: Attenuated the decreased food consumption induced by the intracerebroventricular injection of ghrelin. |
| References |
|
| Molecular Formula |
C5H11LINO5P
|
|---|---|
| Molecular Weight |
203.06
|
| CAS # |
125229-62-1
|
| Related CAS # |
D-AP5;79055-68-8;DL-AP5;76326-31-3;DL-AP5 sodium;1303993-72-7;L-AP5
|
| SMILES |
[Li].C(CC(C(=O)O)N)CP(=O)(O)O
|
| Synonyms |
2-APV lithium; DL-2-Amino-5-phosphonovaleric acid lithium
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9247 mL | 24.6233 mL | 49.2465 mL | |
| 5 mM | 0.9849 mL | 4.9247 mL | 9.8493 mL | |
| 10 mM | 0.4925 mL | 2.4623 mL | 4.9247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
